A carregar...
Natalizumab in the Treatment of Multiple Sclerosis
Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42-54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing-remitting multiple sclerosis (RRMS). Natalizumab is generally well tolerated, but due to rare and potent...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3002624/ https://ncbi.nlm.nih.gov/pubmed/21180646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285608101861 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|